Table 3 Events after diagnosis of SRH in PPFE
From: Impact of sleep-related hypoventilation in patients with pleuroparenchymal fibroelastosis
Events | n |
|---|---|
Respiratory complications | |
Pneumothorax | 7 (25.0%) |
Bacterial pneumonia | 4 (14.3%) |
CPA | 3 (10.7%) |
Acute exacerbation | 1 (3.5%) |
Death at the end of follow up | 16 (57.1%) |
Reasons of death | |
Worsening of hypercapnia | 11 (68.7%) |
Pneumothorax | 3(18.7%) |
Acute exacerbation | 1 (6.2%) |
Sepsis | 1 (6.2%) |
Introducing drug therapy | |
Nintedanib | 3 (10.7%) |
Alive after introducing | 0 (0%) |
Death after introducing | 3 (100%) |
Pirfenidone | 2 (7.1%) |
Alive after introducing | 1 (50%) |
Death after introducing | 1 (50%) |
Prednisolone | 0 (0%) |
Immunosuppressant (tacrolimus) | 1 (3.5%) |
Alive after introducing | 1 (100%) |
Death after introducing | 0 (0%) |
Introducing home ventilator | |
HOT + NPPV | 9 (32.1%) |
Alive after introducing | 3 (33.3%) |
Death after introducing | 5 (55.5%) |
Untraceable because of transferring another hospital | 1 (11.1%) |